Project Grant K23AG090757
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $1,275,512 to The Regents of the University of California, San Francisco (UCSF) to conduct research on understanding how changes in progranulin (PGRN) protein species impact the accumulation of the TDP-43 protein, which is associated with neurodegenerative disorders like Alzheimer's disease and frontotemporal dementia. The research aims to elucidate the role of lysosomes and lysosomal...
- The National Institute on Aging (NIA), through its Aging Research federal grant program (CFDA 93.866), awarded a $630,496 project grant to the J. David Gladstone Institutes to conduct research on proteostasis, neuroinflammation, and neurodegeneration in frontotemporal dementia (FTD). The research aims to better understand how GRN haploinsufficiency, a key genetic factor in FTD, impairs the autophagy/lysosomal pathway and ubiquitin proteasome system, leading to accumulation of toxic proteins,...
- This Project Grant award of $328,000 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports the Alzheimer's Disease Organelle Proteome Task (ADOPT) pilot phase. The interdisciplinary research team, led by Drs. Biao Wang and Danielle Swaney at the University of California, San Francisco, will use a genetic organelle tagging approach to rapidly purify lysosomes from neurons in wild-type and Alzheimer's disease mouse models. A suite of mass spectrometry experiments will then...
- This three-year, $5.782 million project grant from the National Institute on Aging, part of the Department of Health and Human Services, will support research into single-cell characterization of frontotemporal lobar degeneration caused by mutations in the progranulin gene. The University of California, San Francisco will map the transcriptome and gene regulatory networks that define glial pathology and neuronal vulnerability in the frontal cortex and thalamus of progranulin-deficient...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) for $791,086 aims to develop computational models that can predict the presence of non-Alzheimer's disease neuropathological changes, such as Lewy body disease, TDP-43 proteinopathy, and cerebral amyloid angiopathy, in individuals with Alzheimer's disease neuropathological changes. The project will leverage data from autopsy-confirmed datasets, in vivo neuroimaging, and clinical assessments to build...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) for $124,050 supports research to elucidate the molecular mechanisms underlying synapse loss in Alzheimer's disease (AD). The award will fund the development of a novel pooled CRISPR screening platform to systematically investigate regulators of synaptic phosphatidylserine (PS) exposure, a key driver of glial-mediated synapse removal in AD models. Specifically, the research aims to determine how IL-6 and...
- This $816,661 Project Grant award, issued on June 1, 2025 by the National Institute on Aging (CFDA 93.866 Aging Research program), supports comprehensive research aimed at elucidating the molecular mechanisms underlying tauopathies such as Alzheimer's disease and frontotemporal dementia. The project, titled "Aberrant Proteomes in Tauopathy: Revealing Functional Consequences via Multimodal Proteomics", combines expertise in mass spectrometry-based proteomics and functional genomics to...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports a $163,080 research project titled "Bridging Gaps to Translate Plasma Alzheimer's Disease Biomarkers to Diverse Populations." The project, led by the University of Texas Health Science Center at San Antonio, aims to address critical gaps in understanding the performance of plasma biomarkers for Alzheimer's disease and related dementias in diverse population cohorts, including in the...
- This Project Grant award of $437,875 from the National Institute on Aging's Aging Research program (CFDA 93.866) will fund a 2-year research project at the University of California, San Diego to quantify neurovascular protein lifetimes in the central nervous system under healthy, aging, and Alzheimer's disease conditions. The key objectives are to generate a comprehensive atlas of neurovascular protein lifetimes and identify changes associated with aging and Alzheimer's disease. The project will...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $760,207 to the Methodist Hospital Research Institute (HMRI) to conduct a multi-omic integrative analysis of inflammation networks across Alzheimer's disease (AD) and frontotemporal dementia (FTD). The goal is to gain a comprehensive molecular understanding of inflammatory cascades and networks in these neurodegenerative disorders, which may identify novel interventional strategies....
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $199,830 to support Dr. Rowan Saloner's research to identify fluid biomarker signatures associated with the progression of frontotemporal lobar degeneration (FTLD) and other age-related dementias. The award will fund a multi-year effort by Dr. Saloner and his research team at the University of California, San Francisco Memory and Aging Center to conduct large-scale proteomics, clinical characterization, and bioinformatics analyses to understand the molecular underpinnings of FTLD and related dementias. The goal is to develop personalized biomarkers that can aid in disease diagnosis, prognosis, and therapeutic target engagement. This work builds on Dr. Saloner's training and expertise in neurobehavioral aging, ADRD fluid biomarkers, proteomics, and disease progression modeling.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $199.8k | 9/10/25 |